ACRV news & sentiment — Acrivon Therapeutics, Inc.

MAY 19·Stock TitanLow

[Form 4] Acrivon Therapeutics, Inc. Insider Trading Activity

Acrivon Therapeutics, Inc.'s Chief Operating Officer, Eric Devroe, had 613 shares of Common Stock withheld on May 14, 2026, to cover tax obligations related to restricted stock unit vesting. The shares were valued at $1.92 each for this administrative tax-withholding disposition, which is not an open-market sale. Following this transaction, Devroe directly holds 73,972 Common Stock shares, maintaining his equity position after satisfying the required tax liability.

MAR 23·Stock Titan

If You Invested $1,000 in Acrivon Therapeutics, Inc. (ACRV)

This article analyzes the historical performance of investing $1,000 in Acrivon Therapeutics, Inc. (ACRV) over one, five, and ten years, showing significant losses and underperformance compared to the S&P 500. It also provides a detailed overview of Acrivon Therapeutics, explaining its proprietary Generative Phosphoproteomics AP3 platform, its lead clinical candidates ACR-368 and ACR-2316, and its preclinical pipeline. The company is a clinical-stage biopharmaceutical firm focused on precision oncology using AI-driven drug discovery and companion diagnostics.

OCT 22·Benzinga

Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference - Acrivon Therapeutics ( NASDAQ:ACRV )

AP3 Generative AI KaiSR model globally assesses drug effects on the entire intracellular protein signaling network for optimal drug design and precision medicine development

$ACRV

[Form 4] Acrivon Therapeutics, Inc. Insider Trading Activity

If You Invested $1,000 in Acrivon Therapeutics, Inc. (ACRV)

Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference - Acrivon Therapeutics ( NASDAQ:ACRV )

News on $ACRV